In Reply We truly appreciate the comments from Dr Sari et al regarding our randomized clinical trial1 and for indicating previous valuable works in the field. Indications and modalities of adjuvant treatment for early-stage cervical cancer, such as radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), were debatable because the evidence was limited, especially at the time the study was designed and initiated 13 years ago. For example, according to German Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie) guidelines,2 patients with 1 intermediate-risk factor (tumor size > 4 cm, deep stromal invasion, or extensive lymphatic vascular involvement) would be indicated to receive CCRT as the adjuvant therapy. However, at least 2 intermediate-risk factors were needed for the indication of adjuvant radiotherapy according to Sedlis criteria.3 Moreover, chemoradiotherapy with weekly single cisplatin has been more widely adopted for primary treatment of locally advanced cervical cancer in clinical practice,4 which to our knowledge has not been investigated in any randomized clinical trials for adjuvant treatment. In the Gynecologic Oncology Group GOG109 study,5 patients received chemoradiotherapy with a combination of fluorouracil and cisplatin but not with weekly cisplatin. Therefore, it was just the rationale and purpose of our study1 to investigate different modalities for risk-adapted postoperative treatment in early-stage cervical cancer.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Huang H, Feng Y, Liu J. Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer—Reply. JAMA Oncol. 2021;7(9):1404–1405. doi:10.1001/jamaoncol.2021.2113
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.